Delta-Fly Pharma, Inc. (TYO:4598)
Japan · Delayed Price · Currency is JPY 99.00
-1.00 (-1.00%)
Oct 9, 2026, 3:30 PM JST
Delta-Fly Pharma Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Assets
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 83 | 145 | 338 | 1,417 | 844 | 1,268 |
Cash & Short-Term Investments | 83 | 145 | 338 | 1,417 | 844 | 1,268 |
Cash Growth | -88.63% | -57.10% | -76.15% | 67.89% | -33.44% | -39.27% |
Other Receivables | 20 | 57 | 51 | - | - | - |
Receivables | 20 | 57 | 51 | - | - | - |
Prepaid Expenses | - | 3 | 2 | 2 | 3 | 5 |
Other Current Assets | 9 | 2 | 3 | 13 | 19 | 7 |
Total Current Assets | 112 | 207 | 394 | 1,432 | 866 | 1,280 |
Property, Plant & Equipment | 34 | 35 | 36 | 38 | 38 | 39 |
Long-Term Investments | 3 | 3 | 2 | 2 | 1 | 3 |
Other Long-Term Assets | 1 | 1 | 2 | 2 | 1 | 2 |
Total Assets | 150 | 246 | 434 | 1,474 | 906 | 1,324 |
Liabilities
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Current Income Taxes Payable | 343 | 210 | 154 | 238 | 113 | 89 |
Other Current Liabilities | 3 | 2 | 2 | 3 | 2 | 2 |
Total Current Liabilities | 346 | 212 | 156 | 241 | 115 | 91 |
Other Long-Term Liabilities | - | 1 | 2 | 2 | 1 | 1 |
Total Liabilities | 346 | 213 | 158 | 243 | 116 | 92 |
Shareholders' Equity
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Common Stock | 5,901 | 5,804 | 5,113 | 4,731 | 3,795 | 3,352 |
Additional Paid-In Capital | 5,881 | 5,784 | 5,093 | 4,711 | 3,775 | 3,332 |
Retained Earnings | -11,980 | -11,557 | -9,931 | -8,210 | -6,780 | -5,451 |
Comprehensive Income & Other | 2 | 2 | 1 | -1 | - | -1 |
Shareholders' Equity | -196 | 33 | 276 | 1,231 | 790 | 1,232 |
Total Liabilities & Equity | 150 | 246 | 434 | 1,474 | 906 | 1,324 |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash (Debt) | 83 | 145 | 338 | 1,417 | 844 | 1,268 |
Net Cash Growth | -88.63% | -57.10% | -76.15% | 67.89% | -33.44% | -39.27% |
Net Cash Per Share | 6.65 | 12.53 | 38.41 | 197.05 | 148.95 | 234.09 |
Filing Date Shares Outstanding | 13.99 | 12.49 | 9.71 | 8.22 | 6.29 | 5.42 |
Total Common Shares Outstanding | 13.99 | 12.49 | 9.71 | 8.22 | 6.29 | 5.42 |
Working Capital | -234 | -5 | 238 | 1,191 | 751 | 1,189 |
Book Value Per Share | -14.01 | 2.64 | 28.42 | 149.72 | 125.68 | 227.33 |
Tangible Book Value | -196 | 33 | 276 | 1,231 | 790 | 1,232 |
Tangible Book Value Per Share | -14.01 | 2.64 | 28.42 | 149.72 | 125.68 | 227.33 |